• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Talkspace Inc.

    3/30/26 5:30:24 PM ET
    $TALK
    Medical/Nursing Services
    Health Care
    Get the next $TALK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    Talkspace, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)




    87427V103

    (CUSIP Number)
    Sharon Beredjick Cohen
    c/o Qumra Capital, 4 HaNevi'im Street,
    Tel Aviv, L3, 6435604
    972-3-6055205

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/09/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    87427V103


    1 Name of reporting person

    QUMRA CAPITAL II, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    8,573,437.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    8,573,437.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    8,573,437.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.2 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Note to 13: Percentage beneficial ownership is based on 165,656,124 shares of the Issuer's common stock, $0.0001 par value per share ("Common Stock"), outstanding as of November 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 6, 2025.


    SCHEDULE 13D

    CUSIP Number(s):
    87427V103


    1 Name of reporting person

    Qumra Capital GP II, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    8,573,437.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    8,573,437.00
    11Aggregate amount beneficially owned by each reporting person

    8,573,437.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.2 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Note to 8, 10, and 11: Consists of the 8,573,437 shares of common stock held by Qumra Capital II, L.P. ("Qumra Capital II"), as to which the Reporting Person shares voting and dispositive power by virtue of serving as the general partner of Qumra Capital II. Note to 13: Percentage beneficial ownership is based on 165,656,124 shares of the Issuer's Common Stock, outstanding as of November 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP Number(s):
    87427V103


    1 Name of reporting person

    Qumra Capital Israel I Ltd.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    8,573,437.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    8,573,437.00
    11Aggregate amount beneficially owned by each reporting person

    8,573,437.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.2 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Note to 8, 10, and 11: Consists of the 8,573,437 shares of common stock held by Qumra Capital II, as to which the Reporting Person shares voting and dispositive power by virtue of serving as the general partner of the general partner of Qumra Capital II. Note to 13: Percentage beneficial ownership is based on 165,656,124 shares of the Issuer's Common Stock, outstanding as of November 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP Number(s):
    87427V103


    1 Name of reporting person

    Erez Shachar
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    373,758.00
    8Shared Voting Power

    8,573,437.00
    9Sole Dispositive Power

    373,758.00
    10Shared Dispositive Power

    8,573,437.00
    11Aggregate amount beneficially owned by each reporting person

    8,947,195.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.4 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to 8, 10, and 11: Consists of the 8,573,437 shares of common stock held by Qumra Capital II, as to which the Reporting Person shares voting and dispositive power by virtue of his serving as a managing partner of Qumra Capital Israel I Ltd. (which serves as the general partner of the general partner of Qumra Capital II). Note to 13: Percentage beneficial ownership is based on 165,656,124 shares of the Issuer's Common Stock, outstanding as of November 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP Number(s):
    87427V103


    1 Name of reporting person

    Boaz Dinte
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    8,573,437.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    8,573,437.00
    11Aggregate amount beneficially owned by each reporting person

    8,573,437.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.2 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to 8, 10, and 11: Consists of the 8,573,437 shares of common stock held by Qumra Capital II, as to which the Reporting Person shares voting and dispositive power by virtue of his serving as a managing partner of Qumra Capital Israel I Ltd. (which serves as the general partner of the general partner of Qumra Capital II). Note to 13: Percentage beneficial ownership is based on 165,656,124 shares of the Issuer's Common Stock, outstanding as of November 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value
    (b)Name of Issuer:

    Talkspace, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    622 Third Avenue, New York, NEW YORK , 10017.
    Item 1 Comment:
    This Amendment No. 1 to Schedule 13D (this "Amendment") amends and supplements the previously filed statement on Schedule 13D filed on July 1, 2021 (as amended and supplemented from time to time, the "Schedule 13D") by the Reporting Persons, relating to the common stock, par value $0.0001 per share (the "Common Stock"), of Talkspace, Inc., a Delaware corporation (the "Issuer" or "Talkspace"). Except as set forth below, all Items of the Schedule 13D remain unchanged. Capitalized terms used but not defined in this Amendment No. 1 shall have the meanings set forth in the Schedule 13D. The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. The Schedule 13D is hereby supplementally amended as follows:
    Item 4.Purpose of Transaction
     
    The second paragraph of Item 4 of the Schedule 13D is hereby amended and replaced by the following: The information provided in Item 6 is incorporated by reference herein.
    Item 5.Interest in Securities of the Issuer
    (a)
    The first sentence of Item 5 of the Schedule 13D is deleted in its entirety. Items 5(a) and 5(b) of the Schedule 13D are each hereby amended and replaced to incorporate by reference the information provided in the cover pages and in response to Item 1 of this Amendment No. 1.
    (b)
    See (a) above.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following: Merger Agreement On March 9, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"). Subject to the terms and conditions of the Merger Agreement, Merger Sub will be merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent. Voting Agreement On March 9, 2026, concurrently with the execution of the Merger Agreement, Parent entered into a voting agreement (the "Voting Agreement") with certain Reporting Persons, solely in their capacities as stockholders of the Issuer, pursuant to which, among other things, the Reporting Persons (collectively, the "Holders"), among other things, agreed to vote all of their shares of the Issuer's Common Stock beneficially owned (i) in favor of adopting the Merger Agreement and any other actions contemplated by the Merger Agreement in respect of which the approval of the Company's stockholders is requested, (ii) against any alternative takeover proposal from a third party and (iii) against any other action that would reasonably likely be intended, or would reasonably be expected, to materially impede, interfere with, delay, postpone, affect in an adverse manner or prevent the consummation of the Merger or the other transactions contemplated by the Merger Agreement. The Voting Agreement will terminate upon the earliest of (i) the valid termination of the Merger Agreement in accordance with its terms, (ii) the Effective Time (as defined in the Merger Agreement), (iii) the entry, without the prior written consent of the applicable Holders, into any material modification or amendment to the Merger Agreement that reduces the amount, changes the form or otherwise adversely affects the consideration payable to such Holders pursuant to the Merger Agreement as in effect on the date of the Voting Agreement and (iv) with respect to any Holder, the mutual written agreement of such Holder and Parent. The foregoing description of the Voting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the form of Voting Agreement, a copy of which is attached as Exhibit 99.1 and is incorporated by reference herein.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 of the Schedule 13D is hereby amended and supplemented by adding the following: 99.1. Form of Voting Agreement (incorporated by reference to Exhibit 99.2 of the Issuer's Form 8-K filed with the Securities and Exchange Commission on March 9, 2026).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    QUMRA CAPITAL II, L.P.
     
    Signature:/s/ Erez Shachar
    Name/Title:Erez Shachar, Managing Partner
    Date:03/30/2026
     
    Qumra Capital GP II, L.P.
     
    Signature:/s/ Erez Shachar
    Name/Title:Erez Shachar, Managing Partner
    Date:03/30/2026
     
    Qumra Capital Israel I Ltd.
     
    Signature:/s/ Erez Shachar
    Name/Title:Erez Shachar, Managing Partner
    Date:03/30/2026
     
    Erez Shachar
     
    Signature:/s/ Erez Shachar
    Name/Title:Erez Shachar
    Date:03/30/2026
     
    Boaz Dinte
     
    Signature:/s/ Boaz Dinte
    Name/Title:Boaz Dinte
    Date:03/30/2026
    Get the next $TALK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TALK

    DatePrice TargetRatingAnalyst
    12/9/2025$3.50Equal Weight
    Barclays
    10/31/2025$5.00Hold → Buy
    Needham
    4/3/2025$5.00Buy
    Canaccord Genuity
    12/9/2024$4.50Overweight
    KeyBanc Capital Markets
    12/4/2024$5.00Outperform
    Mizuho
    11/20/2024$5.00Outperform
    Northland Capital
    7/1/2024Hold
    Needham
    1/3/2024$2.50Equal Weight
    Barclays
    More analyst ratings

    $TALK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Talkspace Inc.

    SCHEDULE 13D/A - Talkspace, Inc. (0001803901) (Subject)

    3/30/26 5:30:24 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Talkspace Inc.

    SCHEDULE 13G/A - Talkspace, Inc. (0001803901) (Subject)

    3/27/26 1:17:24 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    SEC Form 10-K filed by Talkspace Inc.

    10-K - Talkspace, Inc. (0001803901) (Filer)

    3/13/26 9:07:26 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $TALK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Harris Ian Jiro bought $86,037 worth of shares (30,844 units at $2.79), increasing direct ownership by 5% to 615,015 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/5/25 4:00:06 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Cohen Jon R bought $214,500 worth of shares (75,000 units at $2.86), increasing direct ownership by 3% to 2,267,980 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/3/25 9:30:03 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Chief Legal Officer, Secretary Reilly John Charles bought $10,242 worth of shares (3,600 units at $2.85), increasing direct ownership by 0.41% to 889,806 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    2/28/25 9:55:04 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $TALK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $TALK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chief Marketing Officer Watson Katelyn covered exercise/tax liability with 5,550 shares, decreasing direct ownership by 2% to 358,620 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/16/26 9:30:03 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Director Braunstein Douglas L was granted 3,757 shares, increasing direct ownership by 0.18% to 2,083,901 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/3/26 9:30:08 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Director Pawar Madhu was granted 2,147 shares, increasing direct ownership by 0.56% to 388,014 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/3/26 9:30:11 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Barclays initiated coverage on Talkspace with a new price target

    Barclays initiated coverage of Talkspace with a rating of Equal Weight and set a new price target of $3.50

    12/9/25 8:53:40 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Talkspace upgraded by Needham with a new price target

    Needham upgraded Talkspace from Hold to Buy and set a new price target of $5.00

    10/31/25 8:16:48 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Canaccord Genuity initiated coverage on Talkspace with a new price target

    Canaccord Genuity initiated coverage of Talkspace with a rating of Buy and set a new price target of $5.00

    4/3/25 8:18:33 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $TALK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Publicis Health and Talkspace Partner to Improve Treatment Adherence by Addressing Gaps in Social Health and Peer Support

    NEW YORK, March 23, 2026 /PRNewswire/ -- Publicis Health, the world's most connected and data-powered health communications network, today announced a strategic partnership with Talkspace (NASDAQ:TALK) to help life sciences organizations improve treatment adherence and real-world outcomes by addressing gaps in social health and peer support, factors increasingly recognized as significant behavioral and clinical risk drivers. The collaboration leverages Wisdo Health, Talkspace's clinically validated social health and peer support platform, as a core capability within Talkspace's broader care continuum.

    3/23/26 8:03:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Universal Health Services, Inc. to Acquire Talkspace, Inc.

    Industry-leading virtual behavioral healthcare platform accelerates outpatient strategy with expanded access to careKING OF PRUSSIA, Pa. and NEW YORK, March 9, 2026 /PRNewswire/ -- Universal Health Services, Inc. (NYSE:UHS) announced today that it has entered into a definitive agreement to acquire Talkspace, Inc. (NASDAQ:TALK) for $5.25 per share. The enterprise value for the transaction is approximately $835 million, which UHS intends to finance with borrowings pursuant to its existing revolving credit facility. Talkspace is a leading virtual behavioral healthcare company, with

    3/9/26 7:39:00 AM ET
    $TALK
    $UHS
    $UHT
    Medical/Nursing Services
    Health Care
    Hospital/Nursing Management
    Real Estate Investment Trusts

    Talkspace to Participate in Upcoming Investor Conferences

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Talkspace (NASDAQ:TALK), a leading behavioral healthcare company, today announced that members of senior management will participate in the following upcoming investor conferences: The TD Cowen 46th Annual Health Care Conference, being held in Boston, including 1x1 meetings with investors on Monday, March 2, 2026.The Mizuho Healthcare Technology Conference, being held virtually, including 1x1 meetings with investors on Thursday, March 5, 2026.The Barclays 28th Annual Global Healthcare Conference, being held in Miami, including 1x1 meetings with investors and a fireside chat on Tuesday, March 10, 2026 at 2:30pm ET.The KeyBanc Capital Markets Heal

    2/25/26 4:05:00 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $TALK
    Leadership Updates

    Live Leadership Updates

    View All

    Talkspace Partners With Amazon Health Services to Help Millions Discover Mental Health Benefits

    New collaboration aims to improve awareness of, and expand access to, online therapy and psychiatry services to the 150+ million people who have Talkspace as a covered benefit Talkspace (NASDAQ:TALK), a leading online behavioral health care company, today announced a partnership with Amazon Health Services to increase awareness and discoverability of its mental health care services on Amazon.com. Talkspace is the first virtual behavioral health provider to join Amazon Health Services' program to help individuals discover and enroll in their health insurance benefits at no extra cost or for a small copay. With more than 5,000 therapists and providers across 50 states, Talkspace improves acc

    9/17/24 8:00:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Talkspace and the Professional Tennis Players Association Join Forces to Support Mental Health of Athletes Year Round

    Today, Talkspace (NASDAQ:TALK), a leading online behavioral health care company, announced its partnership with the Professional Tennis Players Association (PTPA), global advocates for professional tennis players. Talkspace will serve as the PTPA's exclusive mental health technology partner, granting players, their families, and their support teams free, 24/7 access to Talkspace's self-guided therapy app, Talkspace Go, as well as discounted access to its virtual therapy offering. "Talkspace is honored to join forces with the PTPA as its exclusive mental health provider, dedicated to delivering high-quality, evidence-based support where and when players need it. This collaboration undersco

    8/28/24 9:06:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Talkspace Appoints John Mooney as Chief Product Officer

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Today Talkspace (NASDAQ:TALK), a leading online behavioral health care company, announced the appointment of John Mooney as its new Chief Product Officer, to lead the company's growth initiatives, product strategy and design. Through his work for startup digital health, behavioral health, and diagnostics companies, Mr. Mooney has deep domain expertise in healthcare data, building out platform capabilities and optimizing workflows. "John has spent his career driving innovation for a range of high-growth, high-performing healthcare companies," said Dr. Jon Cohen, Chief Executive Officer, Talkspace. "We look forward to his expertise leveraging dat

    6/5/24 8:00:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $TALK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Talkspace Inc. (Amendment)

    SC 13G/A - Talkspace, Inc. (0001803901) (Subject)

    2/14/24 4:24:23 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Talkspace Inc. (Amendment)

    SC 13G/A - Talkspace, Inc. (0001803901) (Subject)

    2/9/24 7:24:33 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    SEC Form SC 13D/A filed by Talkspace Inc. (Amendment)

    SC 13D/A - Talkspace, Inc. (0001803901) (Subject)

    10/5/23 6:41:35 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $TALK
    Financials

    Live finance-specific insights

    View All

    Talkspace Announces Fourth Quarter and Full Year 2025 Results

    4Q 2025 total revenue grew 29% year-over-year to $63.0 million4Q 2025 net income of $4.8 million and adjusted EBITDA1 of $6.6 million Full-year 2025 total revenue grew 22% year-over-year to $228.9 millionFull-year 2025 net income of $7.8 millionFull-year 2025 adjusted EBITDA1 grew 127% year-over-year to $15.8 million  NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Talkspace, Inc. ("Talkspace" or the "Company") (NASDAQ:TALK), today reported fourth quarter and full year 2025 financial results.   Three Months EndedDecember 31, Year EndedDecember 31,   2025 2024 2025 2024   Results % Variancefrom PriorYear Results % Variancefrom PriorYear (In thousands unless otherwise noted)Unaudited Unaudited  

    2/19/26 8:00:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Talkspace to Report Fourth Quarter and Full Year 2025 Results and Host Conference Call

    NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Talkspace (NASDAQ:TALK),  a leading behavioral healthcare company, today announced that it will release its fourth quarter and full year 2025 results on Thursday, February 19, 2026 before market open and host a conference call to review the results at 8:30am ET. Conference Call DetailsThe conference call will be available via audio webcast at https://investors.talkspace.com/ and can also be accessed by dialing (800) 225-9448 for U.S. participants, or (203) 518-9708 for international participants, and using conference ID TALKQ425. A replay will be available shortly after the call's completion and remain available for approximately 90 days. About

    2/5/26 4:05:00 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Talkspace Announces Third Quarter 2025 Results

    3Q 2025 Total revenue grew 25% year-over-year to $59.4 million driven by 42% year-over-year growth in Payor revenue 3Q 2025 Net income of $3.3 million and adjusted EBITDA¹ of $5.0 million 3Q 2025 Share repurchases of $8.8 million NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Talkspace, Inc. ("Talkspace" or the "Company") (NASDAQ:TALK), today reported third quarter 2025 financial results.   Three Months EndedSeptember 30,  Nine Months EndedSeptember 30,   2025  2024  2025  2024 Unaudited Results  % Variance from Prior Year  Results  % Variance from Prior Year (In thousands unless otherwise noted)            Number of completed Payor sessions during the period  432.2   37%  1,167.3   30%Num

    10/30/25 8:00:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care